Merck & Company (MRK) 55.92 $MRK
The Cost to Treat Cholesterol Plummets, But Will It Last?
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs. Last year, health care payers forked over...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
2 Ways To Invest in This 1 Big Spending Trend
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 12:30PM CDT
Investors are better served ignoring the market's monthly whims and whispers and focusing instead on discovering stocks with long term tailwinds. In biopharma, that means keeping an eye on drug spending trends, which measure both drug prices and...
Got Allergies? FDA to the Rescue
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 9:00AM CDT
Fresh-cut grass is Kryptonite to allergy sufferers, but a new pill from French drug company Stallergenes may get millions of weekend warriors back outdoors this summer. The FDA's approval of Stallergenes' grass-allergy pill, Oralair, offers a...
The Best Dow Stocks to Start 2014
Travis Hoium, The Motley Fool - Motley Fool - Sat Apr 12, 8:00AM CDT
The year 2013 was a great one for stocks, with the Dow Jones Industrial Average returning 30% and the S&P 500 up 32%. But 2014 has had a slow start, and the indexes are down 1% and flat, respectively. The trend this year is toward safer...
JPMorgan's Earnings Disaster Drops the Dow 100 Points
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 11, 1:38PM CDT
Earnings season has swung around hard on the market today, as the Dow Jones Industrial Average tumbled 130 points as of 2:30 p.m. EDT following some ugly numbers from one of America's top big banks. All but a handful of blue-chip stocks are in...
John Daly, Worked With Merck & White House, Receives 5 Stars on Amazon
Marketwire - Fri Apr 11, 11:09AM CDT
When a group of people are together to generate ideas, solve a problem or achieve a goal, most of the time, the best ideas are passed over. Worse, ideas with far less likelihood of success may be selected instead. Why would a group dismiss an option that would be have a greater likelihood of success?
Dow 30 Stock Roundup: Pfizer Drug Trial Dents, P&G Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 11, 10:06AM CDT
The Dow experienced an extremely volatile week due to the erratic behavior of momentum stocks.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry
M2 - Fri Apr 11, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9g8257/market_for_select) has announced the addition of the "GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry" report to their offering. This report focuses on the market for select cardiovascular drugs in the GCC region. Various market drivers in terms of changing lifestyle and rising disease incidence among the population has led to higher consumption of cardiovascular drugs in the region. Sensing the latent market opportunity, global pharma majors such as Novartis, Abbott, AstraZeneca have set up operations in the GCC region through local joint venture and distribution. The $7.6 bn Pharmaceutical industry in the GCC region is poised for major growth in the coming years. Increase in the international crude oil prices and exports of crude and petro products have transformed the GCC economy. The local governments are increasingly focusing on improving the health and living standards of the population. Contraints in local manufacturing capacity and thriving counterfeit drugs market pose a major challenge but improved regulatory mechanism, increase in private sector participation coupled with rising private and public sector outlay and spend on healthcare presents a promising future for the industry. In addition to market forecast upto 2016, the report also provides interesting insights into key molecules used, top brands, drug prices, procurement process among government and retail institutions. The report will serve as a effective guide for the drug companies, distributors, hospitals and other stakeholders who wish to enter the GCC healthcare market. The report also has profiles of companies and distributors in the GCC region. Key Topics Covered: 1. Methodology 2. Report Coverage 3. Glossary of terms 4. Executive summary 5. Healthcare sector in GCC 6. Pharmaceutical market in GCC 7. Cardiovascular market for select drugs in GCC 8. Profiles of key domestic pharmaceutical manufacturers 9. Annexure - Drugs price details by country - 2012 Companies Mentioned: - AstraZeneca - Global Pharma - Jamjoom Pharma - Julphar - Gulf Pharmaceutical Industries - Kuwait Saudi Pharmaceutical Industries - Merck & Co., Inc - National Pharmaceutical Industries Co - Neo Pharma - Novartis International AG - Oman Pharmaceutical Products Co. L.L.C - Pfizer, Inc - Sanofi S.A. - Saudi Pharmaceutical Industries & Medical Appliances Corporation - Tabuk Pharmaceuticals Manufacturing Company For more information visit http://www.researchandmarkets.com/research/9g...for_select
Merck Shouts "Me, Too!" But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 8:30AM CDT
Merck has rolled out impressive phase 2 data that shows that it too has a very compelling hepatitis C regimen that may eliminate the use of side-effect laden Peginterferon and ribavirin -- the standard of care just a few short years ago. But...
Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts
Business Wire - Fri Apr 11, 8:00AM CDT
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Global Monoclonal Antibodies Market in Colorectal Cancer 2013-2019
M2 - Fri Apr 11, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxqxqg/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth" report to their offering. The global market has the potential to grow to a value of $5.5 billion by 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. Scope - A brief introduction to colorectal cancer, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms. - In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy. - A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets. - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints. - Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006. Reasons to buy - Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies. - Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. - Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics. - Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs. - Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market. Marketed Products - Avastin (Bevacizumab) - Hoffman La Roche - Erbitux (Cetuximab) - Bristol-Myers Squibb, Eli Lilly, and Merck KGaA - Vectibix (Panitumumab) - Amgen and Takeda - Heat Map for Marketed Products Key Late-Stage Pipeline Products - IMC-1121B (Ramucirumab) - Eli Lilly and Company - Xilonix - XBiotech - MetMAb (Onartuzumab) - Hoffmann-La Roche - Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo - MK0646 (Dalotuzumab) - Merck - AMG-655 (Conatumumab) - Amgen For more information visit http://www.researchandmarkets.com/research/zxqxqg/monoclonal
Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Business Wire - Fri Apr 11, 12:00AM CDT
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Interim analysis of hard-to-cure(1) patients administered MK-5172/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response(2) (SVR), 4 to 8 weeks after the completion of therapy (SVR4/
:
Merck renews commitment to the education of tomorrow's scientific innovators
CNW Group - Thu Apr 10, 4:34PM CDT
Merck is proud to once again be a partner of the Super Expo?sciences Hydro-Québec provincial final, whose 2014 edition starts today at Cégep régional de Lanaudière à Terrebonne.
Merck Up on Encouraging HCV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:30PM CDT
Merck presented additional data from an ongoing phase II study on MK-5172 and MK-8742.
Merck Hepatitis C Combo Scores 98% Cure Rate
at Investor's Business Daily - Thu Apr 10, 10:48AM CDT
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with...
May 30th Options Now Available For Merck (MRK)
at The Street - Thu Apr 10, 9:57AM CDT
Investors in Merck & Co., Inc saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options chain for the new May 30th contracts and identified one put...
Dow Today: Merck (MRK) Leads The Day Higher, Chevron (CVX) Lags
at The Street - Thu Apr 10, 9:00AM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 65-cent gain (+1.1%) bringing the stock to $57.75. Holding back the Dow today is Chevron (NYSE: CVX ), which is lagging the broader Dow index with a...
The Cost to Treat Cholesterol Plummets, But Will It Last?
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs. Last year, health care payers forked over...
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
2 Ways To Invest in This 1 Big Spending Trend
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 12:30PM CDT
Investors are better served ignoring the market's monthly whims and whispers and focusing instead on discovering stocks with long term tailwinds. In biopharma, that means keeping an eye on drug spending trends, which measure both drug prices and...
Got Allergies? FDA to the Rescue
Todd Campbell, The Motley Fool - Motley Fool - Sat Apr 12, 9:00AM CDT
Fresh-cut grass is Kryptonite to allergy sufferers, but a new pill from French drug company Stallergenes may get millions of weekend warriors back outdoors this summer. The FDA's approval of Stallergenes' grass-allergy pill, Oralair, offers a...
The Best Dow Stocks to Start 2014
Travis Hoium, The Motley Fool - Motley Fool - Sat Apr 12, 8:00AM CDT
The year 2013 was a great one for stocks, with the Dow Jones Industrial Average returning 30% and the S&P 500 up 32%. But 2014 has had a slow start, and the indexes are down 1% and flat, respectively. The trend this year is toward safer...
JPMorgan's Earnings Disaster Drops the Dow 100 Points
Dan Carroll, The Motley Fool - Motley Fool - Fri Apr 11, 1:38PM CDT
Earnings season has swung around hard on the market today, as the Dow Jones Industrial Average tumbled 130 points as of 2:30 p.m. EDT following some ugly numbers from one of America's top big banks. All but a handful of blue-chip stocks are in...
John Daly, Worked With Merck & White House, Receives 5 Stars on Amazon
Marketwire - Fri Apr 11, 11:09AM CDT
When a group of people are together to generate ideas, solve a problem or achieve a goal, most of the time, the best ideas are passed over. Worse, ideas with far less likelihood of success may be selected instead. Why would a group dismiss an option that would be have a greater likelihood of success?
Dow 30 Stock Roundup: Pfizer Drug Trial Dents, P&G Ups Dividend - Analyst Blog
Swarup Gupta - Zacks Investment Research - Fri Apr 11, 10:06AM CDT
The Dow experienced an extremely volatile week due to the erratic behavior of momentum stocks.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry
M2 - Fri Apr 11, 9:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9g8257/market_for_select) has announced the addition of the "GCC Select Cardiovascular Drugs Market 2012-16 - Analysis of the $7.6 Billion Industry" report to their offering. This report focuses on the market for select cardiovascular drugs in the GCC region. Various market drivers in terms of changing lifestyle and rising disease incidence among the population has led to higher consumption of cardiovascular drugs in the region. Sensing the latent market opportunity, global pharma majors such as Novartis, Abbott, AstraZeneca have set up operations in the GCC region through local joint venture and distribution. The $7.6 bn Pharmaceutical industry in the GCC region is poised for major growth in the coming years. Increase in the international crude oil prices and exports of crude and petro products have transformed the GCC economy. The local governments are increasingly focusing on improving the health and living standards of the population. Contraints in local manufacturing capacity and thriving counterfeit drugs market pose a major challenge but improved regulatory mechanism, increase in private sector participation coupled with rising private and public sector outlay and spend on healthcare presents a promising future for the industry. In addition to market forecast upto 2016, the report also provides interesting insights into key molecules used, top brands, drug prices, procurement process among government and retail institutions. The report will serve as a effective guide for the drug companies, distributors, hospitals and other stakeholders who wish to enter the GCC healthcare market. The report also has profiles of companies and distributors in the GCC region. Key Topics Covered: 1. Methodology 2. Report Coverage 3. Glossary of terms 4. Executive summary 5. Healthcare sector in GCC 6. Pharmaceutical market in GCC 7. Cardiovascular market for select drugs in GCC 8. Profiles of key domestic pharmaceutical manufacturers 9. Annexure - Drugs price details by country - 2012 Companies Mentioned: - AstraZeneca - Global Pharma - Jamjoom Pharma - Julphar - Gulf Pharmaceutical Industries - Kuwait Saudi Pharmaceutical Industries - Merck & Co., Inc - National Pharmaceutical Industries Co - Neo Pharma - Novartis International AG - Oman Pharmaceutical Products Co. L.L.C - Pfizer, Inc - Sanofi S.A. - Saudi Pharmaceutical Industries & Medical Appliances Corporation - Tabuk Pharmaceuticals Manufacturing Company For more information visit http://www.researchandmarkets.com/research/9g...for_select
Merck Shouts "Me, Too!" But Will It Matter?
Todd Campbell, The Motley Fool - Motley Fool - Fri Apr 11, 8:30AM CDT
Merck has rolled out impressive phase 2 data that shows that it too has a very compelling hepatitis C regimen that may eliminate the use of side-effect laden Peginterferon and ribavirin -- the standard of care just a few short years ago. But...
Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts
Business Wire - Fri Apr 11, 8:00AM CDT
Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Kenneth C. Frazier, chairman, president and CEO of Merck & Co, Inc., as chairman-elect of the PhRMA Board of Directors, and George A. Scangos, Ph.D., CEO of Biogen Idec, as Board treasurer.
Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo Health Solutions, Pfizer & Purdue Pharma Dominating
M2 - Fri Apr 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bjv7jj/global_pain) has announced the addition of the "Global Pain Management Drugs Market 2014-2018 with Abbott Labs, Eli Lilly, Endo health Solutions, Pfizer & Purdue Pharma Dominating" report to their offering. The Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the main drivers in this market is the increase in global aging population. The rise in aging population has consequently led to an increase in the incidence of diseases such as chronic arthritis, diabetic neuropathy, osteoarthritis, and cancer. R&D activities are increasing due to the strong need for new efficacious and better-tolerated medications. Developing better pain treatments is the main goal of all pain research being conducted by various institutes. Morphine is one such drug that works through the body's natural pain-killing machinery, preventing pain messages from reaching the brain. Patients receiving morphine also face the problem of morphine tolerance. Scientists are working toward the development of a morphine-like drug that will have the pain-deadening qualities of morphine but without the drug's negative side effects, such as sedation and the potential for addiction. Further, the report states that one of the main challenges is the increase in generic competition. The patent expiry of a drug results in the loss of the exclusive market for that drug, leading to a rapid decline in sales. The key vendors dominating this space are: - Abbott Laboratories - Eli Lilly and Co. - Endo Health Solutions Inc. - Pfizer Inc. - Purdue Pharma L.P. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Category - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Other Companies Featured: - Actavis plc - Allergen Inc. - Astra Zenca plc - Baxter International Inc. - Bayer Healthcare AG - Boehringer Ingelheim GmbH - Boston Scientific Corp. - Bristol Myers Squibb Co. - Durect Corp. - F. Hoffmann La Roche Ltd. - Forest Laboratories Inc. - GlaxoSmithKline plc - Hospira Inc. - Johnson & Johnson - Merck & Co. Inc. - Novartis AG - Pain Therapeutics Inc. - Sanofi S.A. - St. Jude Medical Inc. - UCB S.A. - Valeant Pharmaceuticals International Inc. - Zalicus Inc. For more information visit http://www.researchandmarkets.com/research/bj...lobal_pain
Global Monoclonal Antibodies Market in Colorectal Cancer 2013-2019
M2 - Fri Apr 11, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zxqxqg/monoclonal) has announced the addition of the "Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth" report to their offering. The global market has the potential to grow to a value of $5.5 billion by 2019. There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient's lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin, which generated revenues of $6.2 billion in 2012 across a number of oncology indications. While compelling late-stage candidates are absent from the current pipeline, the anticipated rise in total prevalence of colorectal cancer in the top eight markets may inspire further investment. Pricing patterns for mAbs are highly favorable in the US, the largest market for colorectal cancer, and patent expirations are not expected to have a substantial effect on any of the featured markets. Scope - A brief introduction to colorectal cancer, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms. - In-depth analysis of the three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy. - A comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets. - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type, in addition to an in-depth analysis of clinical trial primary endpoints. - Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the colorectal cancer market since 2006. Reasons to buy - Understand the role of mAbs in the treatment of colorectal cancer and their relation to chemotherapies and targeted small molecule therapies. - Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. - Observe the trends in clinical trial duration and size amongst clinical phases and molecule types. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for colorectal cancer therapeutics. - Observe the shift in clinical trial endpoints throughout clinical phases of development, and use this data to potentially influence any future developmental programs. - Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the colorectal cancer mAbs market. Marketed Products - Avastin (Bevacizumab) - Hoffman La Roche - Erbitux (Cetuximab) - Bristol-Myers Squibb, Eli Lilly, and Merck KGaA - Vectibix (Panitumumab) - Amgen and Takeda - Heat Map for Marketed Products Key Late-Stage Pipeline Products - IMC-1121B (Ramucirumab) - Eli Lilly and Company - Xilonix - XBiotech - MetMAb (Onartuzumab) - Hoffmann-La Roche - Anti-DR5 MoAb (Tigatuzumab) - Daiichi Sankyo - MK0646 (Dalotuzumab) - Merck - AMG-655 (Conatumumab) - Amgen For more information visit http://www.researchandmarkets.com/research/zxqxqg/monoclonal
Merck's Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection
Business Wire - Fri Apr 11, 12:00AM CDT
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Interim analysis of hard-to-cure(1) patients administered MK-5172/MK-8742 with and without ribavirin (RBV) for 12 or 18 weeks showed sustained viral response(2) (SVR), 4 to 8 weeks after the completion of therapy (SVR4/
: Merck renews commitment to the education of tomorrow's scientific innovators
CNW Group - Thu Apr 10, 4:34PM CDT
Merck is proud to once again be a partner of the Super Expo?sciences Hydro-Québec provincial final, whose 2014 edition starts today at Cégep régional de Lanaudière à Terrebonne.
Merck Up on Encouraging HCV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:30PM CDT
Merck presented additional data from an ongoing phase II study on MK-5172 and MK-8742.
Merck Hepatitis C Combo Scores 98% Cure Rate
at Investor's Business Daily - Thu Apr 10, 10:48AM CDT
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with...
May 30th Options Now Available For Merck (MRK)
at The Street - Thu Apr 10, 9:57AM CDT
Investors in Merck & Co., Inc saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK options chain for the new May 30th contracts and identified one put...
Dow Today: Merck (MRK) Leads The Day Higher, Chevron (CVX) Lags
at The Street - Thu Apr 10, 9:00AM CDT
The Dow component leading the way higher looks to be Merck (NYSE: MRK ), which is sporting a 65-cent gain (+1.1%) bringing the stock to $57.75. Holding back the Dow today is Chevron (NYSE: CVX ), which is lagging the broader Dow index with a...
